A New Therapeutic Use of High-dose131I-MIBG Therapy as Consolidation Therapy in Pediatric Patients with High-risk Neuroblastoma: The Japanese experience
Purpose: Pediatric high-risk neuroblastoma patients have poor prognoses despite modern multimodality therapy. Novel and more effective therapeutic strategies are required for high-risk neuroblastoma. We retrospectively examined the utility of consolidation therapy with high-dose 131I-meta-iodo-benzy...
Gespeichert in:
| Veröffentlicht in: | The Journal of nuclear medicine (1978) 2019-05, Vol.60 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | The Journal of nuclear medicine (1978) |
| container_volume | 60 |
| creator | Wakabayashi, Hiroshi Kayano, Daiki Inaki, Anri Araki, Raita Maeba, Hideaki Kuroda, Rie Akatani, Norihito Yamase, Takafumi Watanabe, Satoru Hiromasa, Tomo Nishimura, Ryosei Yachie, Akihiro Kinuya, Seigo |
| description | Purpose: Pediatric high-risk neuroblastoma patients have poor prognoses despite modern multimodality therapy. Novel and more effective therapeutic strategies are required for high-risk neuroblastoma. We retrospectively examined the utility of consolidation therapy with high-dose 131I-meta-iodo-benzyl-guanidine (131I-MIBG) against invisible tumor cells on 123I-MIBG scintigraphy in pediatric patients with high-risk neuroblastoma and ganglioneuroblastoma. Materials and Methods: From December 2009 to December 2014, there were nine high-risk pediatric neuroblastoma and one high-risk ganglioneuroblastoma pediatric patients with complete response to primary therapy in diagnostic 123I-MIBG scintigraphy. The nine who received high-dose 131I-MIBG therapy were included in this study. One pediatric patient who received lower-dose 131I-MIBG therapy ( |
| format | Article |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_2236178973</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2236178973</sourcerecordid><originalsourceid>FETCH-proquest_journals_22361789733</originalsourceid><addsrcrecordid>eNqNjcFOAjEURRuiiSP6Dy9x3aSlaWdwp0QFEg0LWJPKPJjC2I59naB_4udaI3Ht6i7OPfcOWCG10lwbU56xQkgjudZCX7BLor0QwlRVVbCvO3jBIywbjLbDPrkNrAghbGHqdg2vA6FUcsafZ_dPp9YnWIJJ8BRaV9vkgv8DzsMCa2dTzDuLzNAngqNLze9cdHTIf30Mr62lFN7s7Y8Lc9tZj_kXPzqM2drgFTvf2pbw-pRDdvP4sJxMeRfDe4-U1vvQR5_RejRSRpbVuFTqf61vncpZNQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2236178973</pqid></control><display><type>article</type><title>A New Therapeutic Use of High-dose131I-MIBG Therapy as Consolidation Therapy in Pediatric Patients with High-risk Neuroblastoma: The Japanese experience</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Wakabayashi, Hiroshi ; Kayano, Daiki ; Inaki, Anri ; Araki, Raita ; Maeba, Hideaki ; Kuroda, Rie ; Akatani, Norihito ; Yamase, Takafumi ; Watanabe, Satoru ; Hiromasa, Tomo ; Nishimura, Ryosei ; Yachie, Akihiro ; Kinuya, Seigo</creator><creatorcontrib>Wakabayashi, Hiroshi ; Kayano, Daiki ; Inaki, Anri ; Araki, Raita ; Maeba, Hideaki ; Kuroda, Rie ; Akatani, Norihito ; Yamase, Takafumi ; Watanabe, Satoru ; Hiromasa, Tomo ; Nishimura, Ryosei ; Yachie, Akihiro ; Kinuya, Seigo</creatorcontrib><description>Purpose: Pediatric high-risk neuroblastoma patients have poor prognoses despite modern multimodality therapy. Novel and more effective therapeutic strategies are required for high-risk neuroblastoma. We retrospectively examined the utility of consolidation therapy with high-dose 131I-meta-iodo-benzyl-guanidine (131I-MIBG) against invisible tumor cells on 123I-MIBG scintigraphy in pediatric patients with high-risk neuroblastoma and ganglioneuroblastoma. Materials and Methods: From December 2009 to December 2014, there were nine high-risk pediatric neuroblastoma and one high-risk ganglioneuroblastoma pediatric patients with complete response to primary therapy in diagnostic 123I-MIBG scintigraphy. The nine who received high-dose 131I-MIBG therapy were included in this study. One pediatric patient who received lower-dose 131I-MIBG therapy (<444 MBq/kg, due to law regulation) was excluded from this study. Some patients received bone marrow rescue after the 131I-MIBG therapy. Overall and event-free survivals at 4-years after the 131I-MIBG therapy of the nine pediatric patients were analyzed by the Kaplan-Meier method. Results: No patient had abnormal uptake on post-therapeutic 131I-MIBG scintigraphy. Six pediatric patients (67%) had no sign of relapse and three pediatric patients (33%) relapsed during the observed period. One non-relapse patient died for side effects of consolidation chemotherapy and 2 relapsed pediatric patients died due to tumor progression. The event-free and overall survival rate from 131I-MIBG therapy was 65% and 78% at 4 years, respectively. No life-threatening side effect of 131I-MIBG therapy except myelosuppression was observed. Conclusions: The consolidation therapy with high-dose 131I-MIBG had good overall and event-free survival in pediatric patients with high-risk neuroblastoma. While we must consider risks of radiation exposure and beta particle range, the high-dose 131I-MIBG therapy as consolidation therapy should be further investigated.</description><identifier>ISSN: 0161-5505</identifier><identifier>EISSN: 1535-5667</identifier><language>eng</language><publisher>New York: Society of Nuclear Medicine</publisher><subject>Beta particles ; Beta rays ; Bone marrow ; Chemotherapy ; Consolidation ; Diagnostic systems ; Guanidine ; Laws ; Myelosuppression ; Neuroblastoma ; Patients ; Pediatrics ; Prognosis ; Radiation effects ; Risk ; Scintigraphy ; Side effects ; Survival ; Tumor cells ; Tumors</subject><ispartof>The Journal of nuclear medicine (1978), 2019-05, Vol.60</ispartof><rights>Copyright Society of Nuclear Medicine May 1, 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782</link.rule.ids></links><search><creatorcontrib>Wakabayashi, Hiroshi</creatorcontrib><creatorcontrib>Kayano, Daiki</creatorcontrib><creatorcontrib>Inaki, Anri</creatorcontrib><creatorcontrib>Araki, Raita</creatorcontrib><creatorcontrib>Maeba, Hideaki</creatorcontrib><creatorcontrib>Kuroda, Rie</creatorcontrib><creatorcontrib>Akatani, Norihito</creatorcontrib><creatorcontrib>Yamase, Takafumi</creatorcontrib><creatorcontrib>Watanabe, Satoru</creatorcontrib><creatorcontrib>Hiromasa, Tomo</creatorcontrib><creatorcontrib>Nishimura, Ryosei</creatorcontrib><creatorcontrib>Yachie, Akihiro</creatorcontrib><creatorcontrib>Kinuya, Seigo</creatorcontrib><title>A New Therapeutic Use of High-dose131I-MIBG Therapy as Consolidation Therapy in Pediatric Patients with High-risk Neuroblastoma: The Japanese experience</title><title>The Journal of nuclear medicine (1978)</title><description>Purpose: Pediatric high-risk neuroblastoma patients have poor prognoses despite modern multimodality therapy. Novel and more effective therapeutic strategies are required for high-risk neuroblastoma. We retrospectively examined the utility of consolidation therapy with high-dose 131I-meta-iodo-benzyl-guanidine (131I-MIBG) against invisible tumor cells on 123I-MIBG scintigraphy in pediatric patients with high-risk neuroblastoma and ganglioneuroblastoma. Materials and Methods: From December 2009 to December 2014, there were nine high-risk pediatric neuroblastoma and one high-risk ganglioneuroblastoma pediatric patients with complete response to primary therapy in diagnostic 123I-MIBG scintigraphy. The nine who received high-dose 131I-MIBG therapy were included in this study. One pediatric patient who received lower-dose 131I-MIBG therapy (<444 MBq/kg, due to law regulation) was excluded from this study. Some patients received bone marrow rescue after the 131I-MIBG therapy. Overall and event-free survivals at 4-years after the 131I-MIBG therapy of the nine pediatric patients were analyzed by the Kaplan-Meier method. Results: No patient had abnormal uptake on post-therapeutic 131I-MIBG scintigraphy. Six pediatric patients (67%) had no sign of relapse and three pediatric patients (33%) relapsed during the observed period. One non-relapse patient died for side effects of consolidation chemotherapy and 2 relapsed pediatric patients died due to tumor progression. The event-free and overall survival rate from 131I-MIBG therapy was 65% and 78% at 4 years, respectively. No life-threatening side effect of 131I-MIBG therapy except myelosuppression was observed. Conclusions: The consolidation therapy with high-dose 131I-MIBG had good overall and event-free survival in pediatric patients with high-risk neuroblastoma. While we must consider risks of radiation exposure and beta particle range, the high-dose 131I-MIBG therapy as consolidation therapy should be further investigated.</description><subject>Beta particles</subject><subject>Beta rays</subject><subject>Bone marrow</subject><subject>Chemotherapy</subject><subject>Consolidation</subject><subject>Diagnostic systems</subject><subject>Guanidine</subject><subject>Laws</subject><subject>Myelosuppression</subject><subject>Neuroblastoma</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>Prognosis</subject><subject>Radiation effects</subject><subject>Risk</subject><subject>Scintigraphy</subject><subject>Side effects</subject><subject>Survival</subject><subject>Tumor cells</subject><subject>Tumors</subject><issn>0161-5505</issn><issn>1535-5667</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNqNjcFOAjEURRuiiSP6Dy9x3aSlaWdwp0QFEg0LWJPKPJjC2I59naB_4udaI3Ht6i7OPfcOWCG10lwbU56xQkgjudZCX7BLor0QwlRVVbCvO3jBIywbjLbDPrkNrAghbGHqdg2vA6FUcsafZ_dPp9YnWIJJ8BRaV9vkgv8DzsMCa2dTzDuLzNAngqNLze9cdHTIf30Mr62lFN7s7Y8Lc9tZj_kXPzqM2drgFTvf2pbw-pRDdvP4sJxMeRfDe4-U1vvQR5_RejRSRpbVuFTqf61vncpZNQ</recordid><startdate>20190501</startdate><enddate>20190501</enddate><creator>Wakabayashi, Hiroshi</creator><creator>Kayano, Daiki</creator><creator>Inaki, Anri</creator><creator>Araki, Raita</creator><creator>Maeba, Hideaki</creator><creator>Kuroda, Rie</creator><creator>Akatani, Norihito</creator><creator>Yamase, Takafumi</creator><creator>Watanabe, Satoru</creator><creator>Hiromasa, Tomo</creator><creator>Nishimura, Ryosei</creator><creator>Yachie, Akihiro</creator><creator>Kinuya, Seigo</creator><general>Society of Nuclear Medicine</general><scope>4T-</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>M7Z</scope><scope>NAPCQ</scope><scope>P64</scope></search><sort><creationdate>20190501</creationdate><title>A New Therapeutic Use of High-dose131I-MIBG Therapy as Consolidation Therapy in Pediatric Patients with High-risk Neuroblastoma: The Japanese experience</title><author>Wakabayashi, Hiroshi ; Kayano, Daiki ; Inaki, Anri ; Araki, Raita ; Maeba, Hideaki ; Kuroda, Rie ; Akatani, Norihito ; Yamase, Takafumi ; Watanabe, Satoru ; Hiromasa, Tomo ; Nishimura, Ryosei ; Yachie, Akihiro ; Kinuya, Seigo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_22361789733</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Beta particles</topic><topic>Beta rays</topic><topic>Bone marrow</topic><topic>Chemotherapy</topic><topic>Consolidation</topic><topic>Diagnostic systems</topic><topic>Guanidine</topic><topic>Laws</topic><topic>Myelosuppression</topic><topic>Neuroblastoma</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>Prognosis</topic><topic>Radiation effects</topic><topic>Risk</topic><topic>Scintigraphy</topic><topic>Side effects</topic><topic>Survival</topic><topic>Tumor cells</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wakabayashi, Hiroshi</creatorcontrib><creatorcontrib>Kayano, Daiki</creatorcontrib><creatorcontrib>Inaki, Anri</creatorcontrib><creatorcontrib>Araki, Raita</creatorcontrib><creatorcontrib>Maeba, Hideaki</creatorcontrib><creatorcontrib>Kuroda, Rie</creatorcontrib><creatorcontrib>Akatani, Norihito</creatorcontrib><creatorcontrib>Yamase, Takafumi</creatorcontrib><creatorcontrib>Watanabe, Satoru</creatorcontrib><creatorcontrib>Hiromasa, Tomo</creatorcontrib><creatorcontrib>Nishimura, Ryosei</creatorcontrib><creatorcontrib>Yachie, Akihiro</creatorcontrib><creatorcontrib>Kinuya, Seigo</creatorcontrib><collection>Docstoc</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biochemistry Abstracts 1</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>The Journal of nuclear medicine (1978)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wakabayashi, Hiroshi</au><au>Kayano, Daiki</au><au>Inaki, Anri</au><au>Araki, Raita</au><au>Maeba, Hideaki</au><au>Kuroda, Rie</au><au>Akatani, Norihito</au><au>Yamase, Takafumi</au><au>Watanabe, Satoru</au><au>Hiromasa, Tomo</au><au>Nishimura, Ryosei</au><au>Yachie, Akihiro</au><au>Kinuya, Seigo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A New Therapeutic Use of High-dose131I-MIBG Therapy as Consolidation Therapy in Pediatric Patients with High-risk Neuroblastoma: The Japanese experience</atitle><jtitle>The Journal of nuclear medicine (1978)</jtitle><date>2019-05-01</date><risdate>2019</risdate><volume>60</volume><issn>0161-5505</issn><eissn>1535-5667</eissn><abstract>Purpose: Pediatric high-risk neuroblastoma patients have poor prognoses despite modern multimodality therapy. Novel and more effective therapeutic strategies are required for high-risk neuroblastoma. We retrospectively examined the utility of consolidation therapy with high-dose 131I-meta-iodo-benzyl-guanidine (131I-MIBG) against invisible tumor cells on 123I-MIBG scintigraphy in pediatric patients with high-risk neuroblastoma and ganglioneuroblastoma. Materials and Methods: From December 2009 to December 2014, there were nine high-risk pediatric neuroblastoma and one high-risk ganglioneuroblastoma pediatric patients with complete response to primary therapy in diagnostic 123I-MIBG scintigraphy. The nine who received high-dose 131I-MIBG therapy were included in this study. One pediatric patient who received lower-dose 131I-MIBG therapy (<444 MBq/kg, due to law regulation) was excluded from this study. Some patients received bone marrow rescue after the 131I-MIBG therapy. Overall and event-free survivals at 4-years after the 131I-MIBG therapy of the nine pediatric patients were analyzed by the Kaplan-Meier method. Results: No patient had abnormal uptake on post-therapeutic 131I-MIBG scintigraphy. Six pediatric patients (67%) had no sign of relapse and three pediatric patients (33%) relapsed during the observed period. One non-relapse patient died for side effects of consolidation chemotherapy and 2 relapsed pediatric patients died due to tumor progression. The event-free and overall survival rate from 131I-MIBG therapy was 65% and 78% at 4 years, respectively. No life-threatening side effect of 131I-MIBG therapy except myelosuppression was observed. Conclusions: The consolidation therapy with high-dose 131I-MIBG had good overall and event-free survival in pediatric patients with high-risk neuroblastoma. While we must consider risks of radiation exposure and beta particle range, the high-dose 131I-MIBG therapy as consolidation therapy should be further investigated.</abstract><cop>New York</cop><pub>Society of Nuclear Medicine</pub></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0161-5505 |
| ispartof | The Journal of nuclear medicine (1978), 2019-05, Vol.60 |
| issn | 0161-5505 1535-5667 |
| language | eng |
| recordid | cdi_proquest_journals_2236178973 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Beta particles Beta rays Bone marrow Chemotherapy Consolidation Diagnostic systems Guanidine Laws Myelosuppression Neuroblastoma Patients Pediatrics Prognosis Radiation effects Risk Scintigraphy Side effects Survival Tumor cells Tumors |
| title | A New Therapeutic Use of High-dose131I-MIBG Therapy as Consolidation Therapy in Pediatric Patients with High-risk Neuroblastoma: The Japanese experience |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T02%3A11%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20New%20Therapeutic%20Use%20of%20High-dose131I-MIBG%20Therapy%20as%20Consolidation%20Therapy%20in%20Pediatric%20Patients%20with%20High-risk%20Neuroblastoma:%20The%20Japanese%20experience&rft.jtitle=The%20Journal%20of%20nuclear%20medicine%20(1978)&rft.au=Wakabayashi,%20Hiroshi&rft.date=2019-05-01&rft.volume=60&rft.issn=0161-5505&rft.eissn=1535-5667&rft_id=info:doi/&rft_dat=%3Cproquest%3E2236178973%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2236178973&rft_id=info:pmid/&rfr_iscdi=true |